Humanigen’s Cytokine Storm Control Drug Shows Positive Results in CAR-T Trial

Burlingame, California-based Humanigen reported positive data from its Phase Ib ZUMA-19 trial of lenzilumab in patients treated with CAR-T in diffuse large B-cell lymphoma (DLBCL). Lenzilumab is being investigated for its ability to tamp down the hyper-immune response known as a cytokine storm. The cytokine storm and neurotoxicity are known potential side effects of CAR-T immuno-oncology therapies.
Read more...

;